MetaVia Inc MTVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
-
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
-
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $1.23
- Day Range
- $1.20–1.32
- 52-Week Range
- $0.97–14.85
- Bid/Ask
- $1.26 / $1.36
- Shares Outstanding
- 6.59M
- Market Cap
- $8.50M
- Volume/Avg
- 3,240 / 80,137
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.metaviatx.com
Valuation
|
Metric
|
MTVA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.24 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
MTVA
Financial Strength
|
Metric
|
MTVA
|
|---|---|
Quick Ratio | 1.99 |
Current Ratio | 2.06 |
Interest Coverage | — |
Quick Ratio
MTVA
Profitability
|
Metric
|
MTVA
|
|---|---|
Return on Assets (Normalized) | −98.18% |
Return on Equity (Normalized) | −190.13% |
Return on Invested Capital (Normalized) | −191.52% |
Return on Assets
MTVA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^ghLYTh | LOCK|$>vZs | $130B | |||
| Moderna Inc
MRNA
| LOCK|g<QjsQ | LOCK|@?& | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|YZ!pHyS | LOCK|S&!#F | $83B | |||
| argenx SE ADR
ARGX
| LOCK|>Tj%N! | LOCK|^# | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%!$$lzB | LOCK|gK | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|H!#Qpnp | LOCK|!VhN> | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|B#$mVfjT | LOCK|l<k@G | $28B | |||
| Incyte Corp
INCY
| LOCK|m^&##> | LOCK|&!# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|XTL^xC | LOCK|Yw | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%W&x%N^ | LOCK|B#> | $14B |
United States